Literature DB >> 15363989

Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats.

Katarzyna Stachowicz1, Kinga Kłak, Aleksandra Kłodzińska, Ewa Chojnacka-Wojcik, Andrzej Pilc.   

Abstract

We examined the potential anxiolytic-like activity of (-)-N-phenyl-7-(hydroxyimino) cyclopropa[b]chromen-1a-carboxamide (PHCCC), an allosteric modulator of metabotropic glutamate4 receptors (mGlu4), after administration into the basolateral amygdala, using the conflict drinking Vogel test in rats as a model. The results indicate that PHCCC, but not 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester (CPCCOEt), the selective antagonist of group mGlu1 receptors, showed significant, dose-dependent anticonflict effects without affecting the threshold current or water intake. The results indicate that positive allosteric modulation of mGlu4 receptors may be a useful therapeutic approach to anxiety.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363989     DOI: 10.1016/j.ejphar.2004.07.001

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4.

Authors:  Richard Williams; Ya Zhou; Colleen M Niswender; Qingwei Luo; P Jeffrey Conn; Craig W Lindsley; Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2010-06-16       Impact factor: 4.418

Review 2.  Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Authors:  James N C Kew; John A Kemp
Journal:  Psychopharmacology (Berl)       Date:  2005-02-25       Impact factor: 4.530

Review 3.  Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders.

Authors:  Liyun Wang; Bronwen Martin; Randall Brenneman; Louis M Luttrell; Stuart Maudsley
Journal:  J Pharmacol Exp Ther       Date:  2009-08-10       Impact factor: 4.030

Review 4.  Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.

Authors:  John H Krystal; Sanjay J Mathew; D Cyril D'Souza; Amir Garakani; Handan Gunduz-Bruce; Dennis S Charney
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

Review 5.  Allosteric modulation of metabotropic glutamate receptors.

Authors:  Douglas J Sheffler; Karen J Gregory; Jerri M Rook; P Jeffrey Conn
Journal:  Adv Pharmacol       Date:  2011

Review 6.  mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.

Authors:  Corey R Hopkins; Craig W Lindsley; Colleen M Niswender
Journal:  Future Med Chem       Date:  2009-06       Impact factor: 3.808

7.  Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead.

Authors:  Richard Williams; Colleen M Niswender; Qingwei Luo; Uyen Le; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2008-12-25       Impact factor: 2.823

Review 8.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10

9.  Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators.

Authors:  Colleen M Niswender; Evan P Lebois; Qingwei Luo; Kwangho Kim; Hubert Muchalski; Huiyong Yin; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2008-08-29       Impact factor: 2.823

10.  Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.

Authors:  Mikhail Kalinichev; Emmanuel Le Poul; Christelle Boléa; Françoise Girard; Brice Campo; Massimiliano Fonsi; Isabelle Royer-Urios; Susan E Browne; Jason M Uslaner; Matthew J Davis; Jacob Raber; Robert Duvoisin; Simon T Bate; Ian J Reynolds; Sonia Poli; Sylvain Celanire
Journal:  J Pharmacol Exp Ther       Date:  2014-06-19       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.